I
INDV
Indivior Pharmaceuticals Inc
33.89
-0.55-1.60%After Hours: 33.50 -0.39 -1.15%19:04 02/20 EST
OPEN/PREV CLOSE34.61/34.44
TODAY RANGE33.85-34.94
VOL1.51M
MARKET CAP4.23B
52 WEEK RANGE7.62-38.00
AVG VOL (3M)2.32M
% TURNOVER1.21%
TURNOVER--
P/E (TTM)37.37
% RANGE3.16%
EPS(TTM)0.9068
P/E(FORWARD)19.26
P/B-20.4650
BVPS-1.6560
DIVIDEND--
P/S3.566
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.07B
SHARES OUTSTANDING124.85M
NEXT EARNINGS02/18-02/23
FREE FLOAT120.19M
LOT SIZE1
EX-DATE10/11/2022
News
Press Releases
Financial Reports
Profile
Simply Wall St·01/27 08:16
Will Indivior’s (INDV) US Headquarters Shift and Larger ESOP Shelf Reshape Its Corporate Narrative?
TipRanks·01/26 12:33
Indivior Completes U.S. Domestication and Governance Realignment
TipRanks·01/26 12:15
Indivior announces completion of redomiciliation to U.S.
Seeking Alpha·01/21 19:36
MRNA is S&P 500’s top performing stock, here are the best Quant pharma companies
Benzinga·01/21 09:54
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks
TipRanks·01/20 14:10
Indivior price target raised to $50 from $40 at Northland
Simply Wall St·01/17 20:27
Assessing Indivior (NasdaqGS:INDV) Valuation After Recent Share Price Swings And DCF Upside Potential
Seeking Alpha·01/14 19:33
Grail and Indivior PLC come out on top in Healthcare quant picks ahead of Q4 earnings
NASDAQ·01/13 14:19
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
NASDAQ·01/12 15:14
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
NASDAQ·01/12 15:08
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
Dow Jones·01/12 11:27
Indivior Price Target Raised to $48.00/Share From $35.00 by HC Wainwright & Co.
Same Industry
Name/Symbol
Change%
Price